Navigation Links
New CDC Guidelines for Prevention of Intravascular Catheter-Associated Infections Designate Chlorhexidine Gluconate-Impregnated Sponge as a Category 1B Recommendation Exclusively Based on Evidence Related to BIOPATCH® Protective Disk With CHG

SOMERVILLE, N.J., April 1, 2011 /PRNewswire/ -- Ethicon, Inc., announced today that the CDC has reviewed clinical data from patients treated with BIOPATCH® Protective Disk with CHG as part of its update to the 2002 guidelines for reducing risk of intravascular catheter-associated infections in the United States. In the new guidelines, use of a CHG sponge dressing is designated as a Category 1B recommendation. BIOPATCH® is the only CHG-impregnated sponge dressing clinically proven to reduce central line-associated bloodstream infections (CLABSIs) and the only CHG-impregnated product with an FDA-cleared indication for this use.

The CDC's 2011 Guidelines for the Prevention of Intravascular Catheter-Related Infections defines a recommendation classified as Category 1B as "strongly recommended for implementation and supported by some experimental, clinical, or epidemiologic studies and a strong theoretical rationale." BIOPATCH® Protective Disk with CHG, distributed by Ethicon, Inc., has been shown to reduce the risk of CLABSIs in controlled, randomized clinical trials involving more than 4,000 patients.

"The new guidelines reinforce the findings from multiple clinical studies that have shown that BIOPATCH® is proven safe and effective in reducing the risk of CRBSIs in patients with central venous or arterial catheters. No other CHG dressing product on the market has been clinically proven to reduce this risk, and we are very pleased that the Category 1B recommendation has been based on clinical evidence related only to BIOPATCH®," said Earl Adamy, director of BIOPATCH®  sales and marketing at Ethicon.

The guidelines indicate that patients should be treated with "a chlorhexidine-impregnated sponge dressing for temporary short-term catheters in patients older than 2 months of age, if the CLABSI rate is not decreasing despite adherence to basic prevention measures, including education and training, appropriate use of chlorhexidine for skin antisepsis, and MSB [maximal sterile barrier precautions]. Category IB." Guidelines also specify "no recommendation is made for other types of chlorhexidine dressings (Unresolved Issue)."

In the United States, approximately 250,000 CLABSIs are estimated to occur each year. CLABSIs are associated with high mortality rates (12-25%), and extended hospital stays, requiring patients to spend an estimated 9-12 additional days in a hospital. According to the CDC, the cost of treating a single episode of CLABSI can range from $34,508 - $56,000. The average cost of the BIOPATCH® Protective Disk with CHG product is approximately $6.

"Our skin provides very effective protection against infection, but when the skin barrier is broken and a catheter is inserted into vascular tissue, the risk of bacteria migrating down the catheter itself or the catheter tract into the bloodstream increases significantly. BIOPATCH® has a unique proprietary design that allows for 360-degree contact with the skin and continuous delivery of CHG around the site of catheter insertion," said William Jarvis, MD, former acting director of the CDC's Hospital Infections Program and the former assistant chief of the National Nosocomial Infections Surveillance (NNIS) system.*

The safety and effectiveness of BIOPATCH® have not been established for children less than 16 years of age. The protective disk is not to be used on premature infants or on patients with a known sensitivity to CHG.

BIOPATCH® is marketed by Ethicon, Inc., a trusted, worldwide leader in surgical care. For over a century, Ethicon has continuously introduced innovations for wound closure, general surgery, wound management, women's health and urology and aesthetic medicine that fulfill the Company's vision: restoration of body and of life. For more information visit

* Paid consultant to Ethicon, Inc.

Media Contact:
Bill Berry
Berry & Company

SOURCE Ethicon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Genesis Biopharma Expresses Support for FDA Codevelopment Guidelines
2. Health Robotics i.v.STATION Certified as the Only Robot to Comply with Security Guidelines for Controlled Substances
3. Adventus Group Issues Guidelines Surrounding Use of Zero Valent Iron with Emulsified Vegetable Oil
4. ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ
5. Physician's Organization Makes History by Publishing U.S.'s First Adult Stem Cell Guidelines (ASCTA Drives Safe Stem Cell Practices)
6. FRC: NIH Stem Cell Guidelines Reflect Poor Science, Ignore Real Hope for Patients
7. International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia"
8. The International Society for Stem Cell Research Releases New Guidelines to Shape Future of Stem Cell Therapy
9. British School Kids With Diabetes Gain First Time Freedom From Injections With New Insulin Pump Guidelines
10. Soligenix Receives FDA Orphan Drug Designation for RiVax™ for the Prevention of Ricin Intoxication
11. HumanTouch Expands Services to the Centers for Disease Control and Prevention as a Prime Contract Holder as Part of $1.0 Billion Contract
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software as ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and video ... trial team. , Using the CONSULT module, patients and physicians can schedule a face ...
(Date:6/27/2016)... --  Ginkgo Bioworks , a leading organism design ... awarded as one of the World Economic Forum,s ... innovative companies. Ginkgo Bioworks is engineering biology to ... in the nutrition, health and consumer goods sectors. ... including Fortune 500 companies to design microbes for ...
(Date:6/24/2016)... Raleigh, NC (PRWEB) , ... June 24, 2016 , ... ... find the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings ... here to read it now. , Diagnostic biomarkers are signposts in the blood, ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
Breaking Biology Technology:
(Date:6/22/2016)... 2016 On Monday, the Department of Homeland ... share solutions for the Biometric Exit Program. The Request ... Protection (CBP), explains that CBP intends to add biometrics ... the United States , in order to deter ... Logo - ...
(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
(Date:6/9/2016)... June 9, 2016 Paris ... Teleste,s video security solution to ensure the safety of people ... during the major tournament Teleste, an international ... and services, announced today that its video security solution will ... to back up public safety across the country. The system ...
Breaking Biology News(10 mins):